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Abstract
Short-term antiviral therapy with the nucleoside analogue entecavir (ETV), given at an early stage of duck hepatitis B virus (DHBV) infection,
restricts virus spread and leads to clearance of DHBV-infected hepatocytes in ∼50% of ETV-treated ducks, whereas widespread and persistent
DHBVinfection develops in 100% of untreated ducks. To increase the treatment response rate, ETV treatment was combined in the current studywith
a post-exposure “prime-boost” vaccination protocol. Four groups of 14-day-old ducks were inoculated intravenously with a dose of DHBV
previously shown to induce persistent DHBV infection. One hour post-infection (p.i.), ducks were primed with DNAvaccines that expressed DHBV
core (DHBc) and surface (pre-S/S and S) antigens (Groups A, B) or the DNAvector alone (Groups C, D). ETV (Groups A, C) or water (Groups B, D)
was simultaneously administered by gavage and continued for 14 days. Duckswere boosted 7 days p.i. with recombinant fowlpoxvirus (rFPV) strains
also expressing DHBc and pre-S/S antigens (Groups A, B) or the FPV-M3 vector (Groups C, D). DHBV-infected hepatocytes were observed in the
liver of all ducks at day 4 p.i. with reduced numbers in the ETV-treated ducks. Ducks treated with ETV plus the control vectors showed restricted
spread of DHBV infection during ETV treatment, but in 60% of cases, infection became widespread after ETV was stopped. In contrast, at 14 and
67 days p.i., 100% of ducks treated with ETV and “prime-boost” vaccination had no detectable DHBV-infected hepatocytes and had cleared the
DHBV infection. These findings suggest that ETV treatment combined with post-exposure “prime-boost” vaccination induced immune responses
that eliminated DHBV-infected hepatocytes and prevented the development of persistent DHBV infection.
© 2007 Elsevier Inc. All rights reserved.Keywords: Hepatitis B virus; Antiviral therapy; Entecavir; Prime boost vaccination; DNA vaccination; Recombinant fowlpoxvirus vaccines; Cell-mediated
immunity; Resolution of infection; Persistent virus infectionIntroduction
Worldwide ∼2 billion people alive today have been infected
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doi:10.1016/j.virol.2007.11.032with HBVexperience a transient infection that is cleared by both
humoral and cell mediated immune responses (CMI). However,
approximately 2–5% of adults, and 90–95% of children exposed
to HBV before the age of 1 year, develop chronic HBV infection
(Bertoletti and Ferrari, 2003; Bertoletti and Naoumov, 2003;
Hoofnagle, 2006; Lavanchy, 2004). Chronic HBV infection
results in increased risks of chronic liver disease, cirrhosis and
progression to hepatocellular carcinoma (Lavanchy, 2004).
Current therapies for chronic HBV infection involve treatment
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nucleoside analogues, lamivudine, adefovir dipivoxil or the
Bristol-Myers Squibb drug, entecavir (ETV) (Boni et al., 2003;
Lai et al., 2002, 2006; Lavanchy, 2004; van Zonneveld et al.,
2004; Yim and Lok, 2006). With these approaches, the rate of
sero-conversion from HBeAg to anti-HBe antibodies which is
accompanied by persistently lower levels of virus replication is
approximately 20%. In the remaining 80% of patients, cessation
of treatment usually results in rebound of HBV infection
(Bertoletti and Naoumov, 2003; Hoofnagle, 2006). There is cur-
rently no effective therapeutic vaccination protocol for chronic
HBV infection.
Duck hepatitis B virus (DHBV) is a member of the hepad-
naviridae family that shares with HBV similarities in genome
structure, virus replication strategy and outcomes of infection
(Bertoletti and Ferrari, 2003; Foster et al., 2005; Jilbert et al.,
1998, 1996, 1992). For example, infection of adult ducks is
usually transient, whereas infection of 14-day-old ducks, gen-
erally leads to widespread and persistent DHBV infection.
DHBV-infected ducks provide a useful model for testing novel
antiviral and vaccine approaches for human HBV infection.
In recent work using the DHBV model, we reported that
treatment of 14-day-old ducks with ETV from the time of DHBV
infection until 14 or 49 days p.i. did not prevent initial DHBV
infection of the liver, but markedly reduced the spread of
infection, and allowed∼50% of ducks to successfully clear their
DHBV infection (Foster et al., 2005). In contrast, all untreated
ducks developed widespread and persistent DHBV infection. It
was concluded from this study that short-term suppression of
virus replication and spread by ETV provided an opportunity for
the host to mount an effective antiviral immune response that
was able to control the infection in at least some ducks.
In a related work, we demonstrated that DNA vaccines
expressing the DHBV pre-S/S and S antigens protected against
subsequent challenge with DHBV in a virus dose-dependent
manner (Miller et al., 2006b), providing significant protective
immunity due to virus neutralization by anti-DHBs antibodies
(Miller et al., 2006a,b; Rollier et al., 2000, 1999; Triyatni et al.,
1998). In an additional study, we showed that pre-exposure
vaccination with whole cell vaccines expressing DHBV core
antigen, prevented the development of persistent DHBV
infection, presumably by stimulating antigen specific CMI that
targeted DHBV-infected hepatocytes (Miller et al., 2006a,b).
Interestingly, a combination of DNA vaccination and ETV
treatment offered no additional therapeutic benefit over ETV
alone in ducks with established and widespread DHBV infection
of the liver (Foster et al., 2003), again suggesting that further
immune stimulation is required to elicit therapeutic responses in
persistently DHBV-infected ducks.
Fowlpox virus (FPV) is the type member of the Avipoxvirus
genus that causes disease in chickens (Gallus domesticus).
“Shuttle vectors” enabling insertion of foreign genes into the
non-essential thymidine kinase gene of the vaccine strain of FPV
(FPV-M3) have previously been constructed (Boyle et al., 2004;
Boyle and Coupar, 1988; Coupar et al., 2006) and used to derive
recombinant FPV-M3 (rFPV) vaccine strains that induce vaccine
specific immune responses in mice (Ramsay et al., 1999),chickens (Boyle andHeine, 1993; Heine and Boyle, 1993; Heine
et al., 1997), macaques (Dale et al., 2004, 2000; Kent et al.,
2000) and humans (Coupar et al., 2006; Dale et al., 2006; De
Rose et al., 2007, 2006; Kelleher et al., 2006). Furthermore,
“priming”with a DNAvaccine followed shortly afterwards with
a rFPV “boost” was shown to enhance both CD4+ and CD8+
immune responses when compared to a dual rFPV “prime” and
“boost” approach (Dale et al., 2004, 2006, 2000; De Rose et al.,
2006; Kent et al., 2005; Ramsay et al., 1999).
As the next step toward developing a potential therapeutic
DHBV vaccine, in the current study, we defined and optimized
short-term combination therapies given to the ducks immedi-
ately after DHBV infection. In these experiments, ETV treat-
ment and a vaccination regime consisting of a “prime” with
DNA vaccines expressing the DHBc and DHBpre-S/S antigens
(Triyatni et al., 1998; vonWeizsacker et al., 1995), followed by a
“boost” with rFPV-M3 strains expressing DHBV core and
surface antigens (rFPV-DHBc and rFPV-pre-S/S) (Boyle et al.,
2004; Boyle and Coupar, 1988; Triyatni et al., 2001), were
administered following DHBV infection. Combination treat-
ment slowed initial spread of DHBV through the liver and also
induced anti-DHBV immune responses that targeted DHBV-
infected hepatocytes and ultimately, prevented development of
persistent DHBV infection in 100% of ducks. The effectiveness
of this combination strategy in DHBV-infected ducks suggests
that similar strategies could be employed to target HBV-infected
hepatocytes in humans.
Results
Construction of rFPV strains expressing DHBV antigens
Recombinant FPV-M3 strains expressing the DHBV core and
surface antigens (rFPV-DHBc and rFPV-pre-S/S) were con-
structed by homologous recombination between the FPV-M3
vaccine strain and the “shuttle vector” pAF09 into which we had
previously cloned the DHBc and pre-S/S genes, as described in
Materials and Methods and as shown in Table 1 and Fig. 1.
Stocks of both rFPV-DHBc and rFPV-pre-S/S were grown in
primary chicken embryonic fibroblasts (PCEF) cell cultures and
the titer of each virus stock was determined as plaque forming
units (p.f.u.) per ml. Infection of PCEF with FPV-M3, rFPV-
DHBc or rFPV-pre-S/S caused widespread cell lysis and partial
destruction of the PCEF monolayers within 24 h of infection,
determined by staining of the monolayer with crystal violet (data
not shown). In contrast, infection of primary duck embryonic
fibroblasts (PDEF) with FPV-M3, rFPV-DHBc or rFPV-pre-S/S
caused no visible cell lysis or cytopathic effects.
Western blot analysis of PCEF and PDEF infected with the
recombinant strains (Fig. 2) confirmed the expression of a DHBc
protein band (33 kDa) with minor degradation product running at
∼26 kDa (Fig. 2B). Expression of the DHBV pre-S/S protein
(36 kDa) was also confirmed. A smaller band migrating at
∼28 kDa has been previously described in DHBV-infected liver
(Rollier et al., 1999) and is thought to result from internal
initiation of translation or post-translational degradation (Triyatni
et al., 2001). PDEFmonolayers, infectedwith the FPV-M3, rFPV-
Table 1
Primers used for PCR mutagenesis, cloning of the DHBc and pre-S/S genes into pAF09 and qPCR
Primer Nucleotide number a Sequence 5′ to 3′
DHBc-UCPb 2563–2580 AGAACAGGATCCATGGATATCAATGCTTCTAGAGCCTTAG
DHBc-DCPb, c 414–393 GGTAGAAGCTTATAAAAATTATTTCCTAGGCGAGGGAGA
Pre-S/S-UCP b 801–829 AGAACGGATCCATGGGACAACAACCTGCAAAATCAATGGA
Pre-S/S-DCP b, c 1793–1767 GGTAGAAGCTTATAAAAACTAATTCTTGTAGAAAAGTGCAGACAG
Pre-S/S-DMP1 d 1370–1325 TTCGAGAATTTTTATCAACAAGAAGAAGCCTACCAGTAATCCGATTA
Pre-S/S-UMP1 d 1325–1366 TAATCGGATTACTGGTAGGCTTCTTCTTGTTGATAAAAATTCT
Pre-S/S-DMP2 d 1551–1505 GCAGGATTAAGAGGAAGATGATGAAAAGCCTGAGATAGGTCCAGAGA
Pre-S/S-UMP2 d 1509–1551 GGACCTATCTCAGG CTTTTCATCATCTTCCTCTTAAT
qPCR-F e 390–410 CAGATCTCCCTCGCCTAGGA
qPCR-R f 666–646 ATTGCCTCATGCTGCATCAC
Seq. 1 (pAF09) g 1331–1351 GCCTCTTCGCTATTACGCCA
Seq. 2 (pAF09) g 1622–1603 ATCGAACTCCATTCCGTGT
a The nt numbers shown for each primer can be referenced to the AusDHBV genome (Genbank sequence AJ0006350 which is numbered from the EcoRI site at nt 1).
b The BamHI and HindIII sites introduced into the 5′ and 3′ ends of the cloning primers are shown in italics.
c Underlined sequences represent the (T5)NT FPV transcription terminator added to the 3′ end of the cloned DHBc and pre-S/S genes. In each case, the
complimentary sequence, (A5)NA, is shown.
d FPV termination sequences, (T5)NT, present in the original pre-S/S gene that were targeted for PCR mutagenesis are shown in bold. The underlined and bolded nt
is the position of the introduced mutation.
e Forward primer used for qPCR detection of DHBV DNA.
f Reverse primer used for qPCR detection of DHBV DNA.
g The plasmids pAF09-DHBc and pAF09-pre-S/S were sequenced in both directions using primers Seq. 1 and Seq. 2 designed within pAF09.
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expression by immunofluoresence. DHBV antigen expression
was not detected in PDEF monolayers infected with FPV-M3. In
contrast, DHBc and pre-S/S were detected in N80% of the PDEF
in each monolayer infected with either the rFPV-DHBc or rFPV-
pre-S/S 24 h after infection (data not shown).
Finally, the cloning vector pAF09 contains theβ-galactosidase
gene under the control of an FPV late promoter. FPV-infected
PCEF and PDEF monolayers were stained for β-galactosidase
as a measure of FPV late gene expression. As expected, β-
galactosidase staining was not detected in monolayers infected
with the FPV-M3 strain, which lacks pAF09. β-galactosidaseFig. 1. PCR mutagenesis and cloning of the DHBc and pre-S/S genes into the “shutt
present in the DHBV pre-S/S gene were mutated by PCR mutagenesis. A FPV transcr
directional cloning was achieved by adding BamHI andHindIII restriction sites to the
and shown in Table 1. The B-galactosidase (B-gal) and FPV thymidine kinase (FPVstaining was detected in∼30% of the surviving cells in the PCEF
monolayer and ∼50% of cells in the intact PDEF monolayers
infected with rFPV-DHBc and rFPV-pre-S/S 24 h after infection
(data not shown). Thus, though cytopathic effects were not seen,
at least some FPV late gene expression occurred in the PDEF
monolayers.
Post-exposure ETV treatment and “prime-boost” vaccination
study
We next tested the ability of a 14-day course of ETV therapy
togetherwith a DNAvaccine “prime” followed by a rFPV “boost”le vector” plasmid AF09. Two FPV transcription terminator sequences, (T5)NT,
iption terminator sequence, TTTTTAT, was added to the 3′ end of each gene and
upstream and downstream cloning primers as described inMaterials andMethods
tk) genes are shown.
Fig. 2. Expression of DHBc and pre-S/S proteins in PCEF and PDEF byWestern blotting. (A) PCEF harvested 96 h after infection with the parent FPV-M3, rFPV-DHBc
and rFPV-pre-S/S strains were analyzed on 4–12% gradient gels and blotted to PVDF membranes. The membrane was probed with polyclonal duck anti-DHBV
antibodies, reacted with secondary rabbit anti-duck IgY antibodies and developed with a sheep anti-rabbit Ig HRP conjugated antibodies. The MagicMark™
Western Standard (M) was simultaneously developed by this process and sizes of each band are shown in kDa. All reacting bands were detected by chemiluminescence.
(B–C) PDEF cultures harvested 48 h after infection with nil, FPV-M3, rFPV-DHBc and rFPV-pre-S/S were analyzed on 12% acrylamide gels. The membranes were
probed with either polyclonal rabbit anti-DHBc antibodies (B, top) or monoclonal mouse anti-DHBV pre-S antibodies (C, top). The samemembranes were analyzed for
protein loading by Western blot using monoclonal anti-human actin antibodies (B, C, bottom). Similar levels of a 42 kDa duck beta actin protein were detected in each
sample.
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infection. A small-scale pilot study was initially carried out in 14-
day-old ducks infected with 5×108 DHBV genomes by intra-
venous inoculation. 5/5 ETV-treated and "prime-boost" vacci-
nated ducks resolved their DHBV infection by day 14 p.i., while
5/5 non-treated control ducks developed widespread DHBV
infection in N95% of hepatocytes by day 14 p.i. (data not shown).
Based on these observations, a more detailed study was carried
out as described below.
To start, 4 Groups (A–D) of 14-day-old ducks were inoc-
ulated intravenously with 5×108 DHBV genomes. At the same
time, oral ETV treatment (1.0 mg/kg/day for 14 days) was
commenced in Groups A and C while ducks in the control
Groups B and D were treated with water. At the same time, a
single “priming” dose of DNAvaccine expressing DHBc, pre-S/
S and S antigens was administered to Groups A and B while the
control ducks (Groups C and D) received the DNA vector
(pcDNA1.1 Amp) alone. Seven days later the ducks in Groups A
and B received a boost with rFPV-DHBc and rFPV-pre-S/S,
while the control ducks (Groups C and D) received the parental
strain, FPV-M3.
At day 4 p.i., ducks in all Groups A to D had detectable
DHBsAg-positive hepatocytes in the liver (Fig. 3, Table 2A).
On average, the percentage of DHBsAg-positive hepatocytes
was about 10-fold lower in the ETV-treated ducks than in those
not treated with ETV (Table 2A: compare Groups A and B and
Groups C and D) and was determined to be statistically
significant with p valuesb0.0001 (Table 3).
Also at day 4 p.i., the average percentage of DHBsAg-
positive hepatocytes was slightly lower in the vaccinated than in
the corresponding unvaccinated ducks (Table 2: compare Group
A with Group C, and Group B with Group D). This result
indicated that unlike the ETV treatment, DNAvaccination givenat the time of infection did not have a major effect on early
DHBV infection of the liver assessed at day 4 p.i.
ETV treatment was then continued for another 10 days, until
day 14 p.i. Again ETV treatment markedly reduced the per-
centage of DHBsAg-positive hepatocytes (Table 2: compare
Group A with Group B and Group C with Group D) and the
differences were highly statistically significant with p values≤
0.0001 (Table 3). Interestingly, the percentage of DHBsAg-
positive hepatocytes in ducks receiving ETV (Group A and
Group C) was lower at day 14 than at day 4 p.i. The percentage
was also lower at day 14 p.i. in the Group A ducks, which
received ETV plus the “prime-boost” vaccination, than in the
Group C ducks, which received ETV plus the control vectors,
suggesting that “prime-boost” vaccination had induced immune
responses that were helping to reduce the percentage of
DHBsAg-positive hepatocytes.
The liver was again analyzed at day 67 p.i., 53 days after
withdrawal of ETV to allow assessment of the outcome of
DHBV infection. At this time, DHBV infection had rebounded
andwas present in N95% of hepatocytes in the liver of 6 of the 10
Group C ducks that received the short course of ETV in
conjunction with the control vectors (Fig. 3, Table 2A). As found
in our previous studies (Foster et al., 2005), DHBVinfection had
cleared from the liver of the remaining 4 out of 10 ducks
(Table 2A). In contrast, in 10/10 Group A ducks, which received
the short course of ETV together with the “prime-boost”
vaccination, DHBsAg-positive hepatocytes were no longer
detected and the difference in outcome of DHBV between the
Group A and Group C ducks was statistically significant with a p
value≤0.0036 (Table 3).
Results of the immunoperoxidase detection of DHBsAg-
positive hepatocytes were confirmed by testing available liver
tissue from 5 ducks in each of Groups A and C for levels of total
Fig. 3. Detection of DHBsAg-positive hepatocytes in EAA-fixed liver tissue collected by biopsy on day 4, and 14 (A-H) and by autopsy on day 67 p.i. (I–L).
Immunostaining of DHBsAg-positive hepatocytes was performed using monoclonal anti-DHBV pre-S antibodies as described in Materials and methods. The
percentage of DHBsAg-positive hepatocytes in one representative duck from each group is indicated. DHBsAg-positive hepatocytes in each panel are indicated with
arrows. Sections were counterstained with hematoxylin. Magnification 200× Bar = 100 uM.
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expected, low levels of DHBV DNA (0.002–0.047 copies per
cell) were detected in all tested ducks from Group A and C on
day 4 p.i. However, by day 14 p.i, only 1/5 of the Group A
ducks had detectable levels of DHBV DNA (0.002 copies per
cell) and in autopsy liver collected on day 67 p.i., 3/5 Group A
ducks had undetectable levels of DHBV DNA, while 2/5 ducks
had low levels of DHBV DNA (0.002 and 0.003 copies per
cell). These low-levels of DHBV DNA are not unexpected as
similar levels of “residual” DHBV DNA have been detected
in the liver of ducks following recovery from acute DHBV
infection (Le Mire et al., 2005; Foster et al., 2005; Reaiche
et al., manuscript in preparation). The biological significance
of residual DHBV DNA is under investigation within the
laboratory.
Also as expected based on the percentage of DHBsAg-
positive hepatocytes, higher levels of DHBV DNA weredetected in liver tissue from the Group C ducks compared to
the Group A ducks on day 14 and 67 p.i. At day 14 p.i., 5/5
Group C ducks had DHBV DNA at 0.001–0.045 copies per cell
(Table 2B), reflecting the higher percentage of DHBsAg-
positive hepatocytes found in the same ducks (Table 2A). By
day 67 p.i., 2/5 Group C ducks had resolved their DHBV
infection and had undetectable levels of DHBVDNAwhile the 3
remaining ducks had DHBV DNA present at 2.25–490 copies
per cell (Table 2B), again reflecting the higher percentage of
DHBsAg-positive hepatocytes (1.53–N95%) (Table 2A).
A different outcome of DHBV infection was observed in the
ducks that either received the control vectors (Group D) or
received the prime-boost vaccination but not ETV (Group B)
(Table 2A). Although samples were not available to test by
qPCR, immunoperoxidase staining showed that all 5 ducks in
Group D and 4 of 5 in Group B had N95% of DHBsAg-positive
hepatocytes by day 14 p.i., and remained fully infected until
Table 3
Statistical analysis of the differences of the percentage of DHBsAg-positive hepatocytes at all time points
Comparison a Day 4 p.i. Day 14 p.i. Day 67 p.i.
Mean differences (95% CI) p value
Group A vs. Group B - ETV+“prime-boost” vs. water+“prime-boost” −2.17 (−3.07, −1.28) −78.34 (−94.41, −62.27) −76.00 (−114.18, −37.83)
pb0.0001 b pb0.0001 b p=0.0002 b
Group C vs. Group D - ETV+control vectors vs. water+control vectors −3.51 (−4.41, −2.62) −94.83 (−110.90, −78.77) −47.35 (−84.99, −9.70)
pb0.0001 c pb0.0001 c p=0.0147 c
Group A vs. Group C - ETV+“prime-boost” vs. ETV+control vectors −0.32 (−1.05, 0.41) −0.17 (−13.29, 12.95) −47.66 (−79.04, −16.27)
p=0.3799 d p=0.9798 d p=0.0036 d
Group B vs. Group D - Water+“prime-boost” vs. Water+control vectors −1.66 (−2.69, −0.63) −16.66 (−35.21, 1.89) −19.00 (−62.47, 24.47)
p=0.0022 p=0.0773 p=0.3844
a Statistical analysis was performed as reported in Materials and methods.
b Differences in the average percentage of DHBsAg-positive hepatocytes between the ducks in Group A vs. Group B were highly statistically significant at all time
points.
c Differences in the average percentage of DHBsAg-positive hepatocytes between the ducks in Group C vs. Group D were highly statistically significant at days 4
and 14 p.i. (p≤0.0001) but were less significant at day 67 p.i. (p=0.0147) due to the rebound of DHBV infection of 40% of Group C ducks by day 67 p.i.
d The percentage of DHBsAg-positive hepatocytes was not significantly different in ducks in Group A vs. Group C at day 4 and 14 p.i. due to the effect of ETV
treatment on reducing the spread of DHBV infection, but was statistically significant at day 67 p.i. (p=0.0036) reflecting the effect of prime-boost vaccination on
altering the outcome of DHBV infection.
Table 2
The outcome of DHBV infection, ETV treatment and “prime boost” vaccination
A. Percentage of DHBsAg-positive hepatocytes
DHBV DNA vaccines+rFPV-DHBc+rFPV-pre-S/S Control vector DNA+FPV-M3
Group Duck Day 4 p.i. Day 14 p.i. Day 67 p.i. Group Duck Day 4 p.i. Day 14 p.i. Day 67 p.i.
% DHBsAg-positive hepatocytes a % DHBsAg-positive hepatocytes a
+ETV A A1 0.52 b0.001 b 0.003 c +ETV C C1 1.23 0.16 b0.001 b
A2 0.33 b0.001 b b0.001 b C2 0.49 0.12 N95
A3 0.14 b0.001 b b0.001 b C3 1.07 0.48 N95
A4 0.26 b0.001 b b0.001 b C4 0.73 0.3 N95
A5 0.38 b0.001 b Died C5 0.82 0.07 b0.002 b
A6 0.09 b0.004 b b0.006 b C6 0.21 0.05 b0.008 b
A7 0.05 b0.003 b b0.003 b C7 0.22 0.08 N95
A8 0.1 b0.003 b b0.007 b C8 0.5 0.31 N95
A9 0.24 b0.003 b b0.007 b C9 0.07 0.03 b0.004 b
A10 0.15 b0.002 b b0.005 b C10 0.14 0.06 1.53
+water B B1 2.1 11.7 b0.001 b +water D D1 2.3 N95 N95
B2 2.8 N95 N95 D2 3.1 N95 N95
B3 3.1 N95 N95 D3 2.8 N95 N95
B4 1.8 N95 N95 D4 5.4 N95 N95
B5 2.2 N95 N95 D5 6.7 N95 N95
B. Levels of total DHBV DNA detected in duck liver by qPCR
DHBV DNA vaccines+rFPV-DHBc+rFPV-pre-S/S Control vector DNA+FPV-M3
Group Duck Day 4 p.i. Day 14 p.i. Day 67 p.i. Group Duck Day 4 p.i. Day 14 p.i. Day 67 p.i.
DHBV DNA copies/cell d DHBV DNA copies/cell d
+ETV A A6 NTe b0.0002 f b0.0002 f +ETV C C6 0.007 0.001 b0.0002 f
A7 0.002 b0.0002 f b0.0002 f C7 0.047 0.008 123.46
A8 0.005 0.002 b0.0002 f C8 0.008 0.045 490.38
A9 NT b0.0002 f 0.002 C9 0.03 0.016 b0.0002 f
A10 NT b0.0002 f 0.003 C10 0.013 0.001 2.25
a The percentage of DHBsAg-positive hepatocytes was determined by immunoperoxidase staining of EAA-fixed liver tissues with anti-pre-S monoclonal antibodies
and counting with an eyepiece graticule as described in the text. The minimum sensitivity of detection of DHBsAg-positive hepatocytes was 0.001%.
b No DHBsAg-positive hepatocytes detected.
c A single DHBsAg-positive hepatocyte was detected in duck A1 at day 67 p.i.
d Levels of total DHBV DNAwere detected in duck liver by qPCR as described in Materials and methods. The minimum sensitivity of the qPCR assay was 10
copies per 52,000 cells or 0.0002 copies/cell.
e NT=not tested.
f The level of total DHBV DNA present in the sample was below the minimum sensitivity of the qPCR assay.
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335D.S. Miller et al. / Virology 373 (2008) 329–341autopsy at day 67 p.i. (Fig. 3). One of 5 ducks in Group B
showed a slightly higher level of infection at day 14 than day 4
p.i., but eventually recovered from the infection (Table 2A). It is
possible that “prime-boost” vaccination resulted in recovery
from DHBV infection in this duck.
In an attempt to detect markers of the immune response that
might contribute to the protection observed in the Group A
ducks, liver tissue was studied to assess levels of infiltrating
mononuclear cells and quantitative reverse transcription PCR
(qRT-PCR) assays were used to determine levels of duck
interferon alpha (IFN-α), interferon gamma (IFN-γ) and theFig. 4. Levels of DHBsAg (A–D), anti-DHBs antibodies (E–H) and anti-DHBc antib
boost” vaccination. All ducks were infected at day 14 of age with 5×108 DHBV geno
antibodies in each group of the vaccinated and control ducks are shown and are expre
at 490 nm. The cut-off for DHBsAg, anti-DHBs and anti-DHBc-positive samples w
assaying normal duck serum. DHBV challenge , DHBV DNAvaccine , control v
water . NB: A colour version of Fig. 4 has been supplied for use as a supplemeduck T-cell markers, CD4 and CD8, mRNA. However, no
significant differences were found in levels mononuclear cell
infiltration or mRNA (data not shown). It is hypothesized that
the failure to detect a difference may in part be due to the timing
of the collection of biopsy samples after rFPV boosting.
Analysis of serum DHBsAg levels confirmed the patterns of
DHBV infection in the liver: Only 1 Group A duck had a low-
level transient rise in DHBsAg on day 63 p.i, whereas the
remaining 9/10 ducks remained DHBsAg-negative throughout
the experiment (Fig. 4A) and liver tissue collected at autopsy
showed that all 10 combination treated ducks had resolved theirodies (I–L) in the serum following DHBV infection, ETV treatment and “prime-
mes then vaccinated in treatment Groups A to D as described in the text. Titers of
ssed as the log of the reciprocal serum dilutions required to achieve an OD of 0.4
as set at two standard deviations above the average background, obtained by
ector DNAvaccine ⇩, rFPV-DHBc+rFPV- , pre-S/S FPV-M3 , entecavir▬,
ntary figure.
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C (Fig. 4C) and 5/5 Group D (Fig. 4D) ducks had detectable
levels of serum DHBsAg reflecting the extensive DHBV
infection in the liver of the same ducks (Table 2).
Titers of anti-DHBs antibodies fluctuated throughout the
experiment in most groups. The ducks in Groups A and B that
received the “prime-boost” vaccine, either in the presence or
absence of ETV developed anti-DHBs antibodies faster
(Figs. 4E and F) than the vector-vaccinated ducks in Groups C
and D (Figs. 4G and H). The ducks that received ETV treatment
in conjunction with “prime-boost” (Group A) maintained low-
levels of anti-DHBs antibodies throughout the study (Fig. 4E).
Many of the ducks in Groups B and C that developed widespread
DHBVinfection had detectable levels of both DHBsAg and anti-
DHBs presumably circulating in the bloodstream as immune
complexes, as previously described (Foster et al., 2003, 2005;
Miller et al., 2006a,b; Surelia and Boxall, 1990; Tsai et al., 1998,
1995). This finding is suggestive of production of anti-DHBs
antibodies albeit at levels insufficient to completely remove
circulating DHBV from the bloodstream. The water treated
Group D ducks had widespread DHBV infection in the liver and
high levels of circulating DHBsAg (Fig. 4D) and the lowest
levels of anti-DHBs antibodies (Fig. 4H).
Titers of anti-DHBc antibodies were also monitored by
ELISA. The ducks in Groups A and B that received the “prime-
boost” vaccine, either in the presence or absence of ETV, again
developed anti-DHBc antibodies faster (Figs. 4I and J) than the
vector-vaccinated ducks in Groups C and D (Figs. 4K and L).
The ducks in Group A and C that received ETV had on average
slightly lower titers of anti-DHBc antibodies, possibly the result
of lower levels of DHBV replication and antigen expression due
to the antiviral effects of ETV.
Discussion
Although post-exposure treatment with Hepatitis B immu-
noglobulin (HBIG) and HBV surface antigen (HBsAg) vaccina-
tion can prevent the development of chronic HBV infection,
vaccination of HBV carriers with the HBV vaccine with or
without supplementary HBIG treatment provides no therapeutic
benefit or change in HBV carrier status (Eren et al., 2000; Galun
et al., 2002; Reed et al., 1973) and there is no effective cure for
chronic HBV infection. The development of new and improved
treatments for chronic HBV infection thus remains a major goal
of HBV research and approaches to activate humoral and CMI
responses in patients with chronic HBV-infection are required.
Ideally, such new treatments might be most effective if they
were given in combination with antiviral drugs that reduce
the virus load and decrease the percentage of HBV-infected
hepatocytes.
Therefore the aim of the current study was to develop and
test a post-exposure antiviral and “prime-boost” vaccination
strategy designed to prevent the development of persistent
DHBV infection by stimulating immune responses that target
and eliminate DHBV-infected hepatocytes.
Using the DHBV model and our knowledge of the dose-
related outcome of DHBV infection in 14-day-old ducks, wepreviously showed that post-exposure treatment with ETV from
the time of DHBVinfection for either 14 or 49 days restricted the
spread of DHBV infection within the liver and prevented the
development of persistent DHBV infection in approximately
50% of ducks infected with 1×106, 1×108 and 5×108 DHBV
genomes (Foster et al., 2005). This finding suggested that short-
term suppression with ETV provides opportunity for the im-
mune response to successfully control DHBV infection. How-
ever, ETV therapy was only able to alter the outcome of infection
in 50% of ducks with the remainder developing widespread and
persistent DHBV infection. Similarly, in the current study, ETV
treatment following infection of 14-day-old ducks with a dose of
5×108 DHBV genomes, prevented the development of
persistent DHBV infection in 40% of ducks in Group C
(Table 2) validating previous results (Foster et al., 2005), but
again indicating that additional immune stimulation needs to be
applied over and above antiviral treatment alone if therapeutic
outcomes are to be achieved.
As the first step in the assessment of rFPV strains for use as
vectors to deliver vaccine antigens in ducks, we tested the
ability of rFPV strains to infect and replicate in PDEF. Infection
of PDEFs with FPV-M3, rFPV-DHBc or rFPV-pre-S/S caused
no visible cell lysis or cytopathic effects. Furthermore, in
contrast to previous reports in chickens (Boyle et al., 1997),
wing web inoculation of rFPV strains into newly hatched ducks
showed no visible lesions. Thus, these in vitro and in vivo
results suggested that rFPV is an efficient and safe vaccine
vector for delivery of vaccine antigens in ducks.
It is currently not clear if the rFPV boost provided additional
immune responses over those observed with DNA vaccination
alone. In preliminary experiments with rFPV strains in our
laboratory, vaccination of ducks with rFPV-DHBc induced low-
level anti-DHBc antibodies while anti-DHBs antibody responses
were not detected following rFPV-pre-S/S vaccination (Darren
Miller and Stephen Blake, unpublished results). This result is not
entirely surprising as titers of anti-DHBs antibodies are generally
lower than anti-DHBc antibodies following recovery from acute
DHBV infection (Foster et al., 2005; Jilbert et al., 1998; Miller
et al., 2006a,b). Therefore, these data are suggestive that the rFPV
boost is contributing to the protection observed in the current
study. In addition, it has been demonstrated that DNAvaccination
followed by a rFPV boost elicited enhanced CMI responses than
either of the delivery vehicles alone (Coupar et al., 2006; Kent
et al., 1998; Ramsay et al., 1999).
Ideally we would like to measure CMI responses in ducks
following vaccination with rFPV constructs as it is hypothesized
that intracellular expression of the rFPV delivered antigens
should elicit potent CMI. Unfortunately, due to a lack of duck
specific reagents, we are at present unable to detect CMI
responses in ducks. It is hoped that the recent availability of
monoclonal antibodies specific for duck CD4 and CD8 will
enhance our understanding of immune mechanisms of DHBV
clearance (Kothlow et al., 2005). Additional ongoingwork in the
laboratory is aimed at answering some of these questions and
also simplifying the combination treatment regime. To this end
we are testing the efficacy of ETV treatment combined with
DNAvaccines and rFPV vaccines alone and also “prime-boost”
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either DHBc or pre-S/S as a single vaccine antigen. Although
multiple vaccine antigens may induce broad humoral and CMI
responses, it is possible that the DHBc or pre-S/S antigens alone
may be sufficient to provide protective or therapeutic immune
responses.
Finally, the results of the study demonstrated that combined
post-exposure treatment with ETV and “prime-boost” vaccina-
tion significantly enhanced the rate of elimination of DHBV-
infected hepatocytes and prevented the development of
persistent DHBV infection in 100% of ducks. The improved
efficacy of the combination ETV and "prime-boost" protocol




Pekin Aylesbury ducks (Anas domesticus platyrhynchos)
were purchased at 1 day of age from commercial hatcheries. All
animal handling procedures and protocols were assessed,
approved and carried out in accordance with the guidelines
of the University of Adelaide and Institute of Medical and
Veterinary Science (IMVS) animal ethics committees and the
National Health and Medical Research Council (NHMRC) of
Australia.
Preparation of DHBV stocks
The DHBV inocula were derived from a pool of serum from
34-day-old congenitally DHBV-infected ducks infected with the
Australian strain of DHBV (AusDHBV; Genbank AJ006350)
(Triyatni et al., 2001). The serum was filtered through a 0.2 μM
filter, aliquoted and stored at −80 °C. The pool of serum was
previously determined to contain 5×109 DHBV genomes/ml and
50 μg/ml of DHBsAg (Jilbert et al., 1996; Meier et al., 2003).
DNA vaccines
The AusDHBV pre-surface (pre-S/S) and surface (S) genes
were cloned into pcDNA1.1Amp as previously described (Triyatni
et al., 1998). Plasmid DNA expressingDHBcAg, pTC-Dcore (von
Weizsacker et al., 1995) was kindly provided by Dr. Fritz von
Weizsacker from the Department of Medicine II, University
Hospital, Freiburg, Germany. All plasmid DNA constructs were
produced in E. coli then purified using a Jetstar Maxi kit
(Genomed-Astral Scientific) and redissolved in distilled water at a
concentration of 1 mg/ml.
PCR amplification of the DHBc gene prior to cloning into
pAF09
Analysis of the AusDHBV core gene (Triyatni et al., 2001)
failed to identify any poxvirus transcription terminator se-
quences, (T5)NT, so the entire DHBc gene from nucleotide (nt)
2563 to 414 was cloned into pAF09 (Boyle et al., 2004; Boyleand Coupar, 1988) using a BamHI restriction enzyme sequence
in the upstream primer (DHBc-UCP) and a HindIII restriction
enzyme sequence in the downstream primer (DHBc-DCP)
(Table 1). The downstream primer also included the poxvirus
transcription terminator sequence, TTTTTAT, shown as its
complimentary sequence, (A5)TA, in Table 1. All PCR re-
actions were performed in a volume of 50 μl and contained
20 μM of both primers and 1× reaction buffer, 200 μM dNTPs,
1.64 mM MgCl2 and 1 U of Pfu polymerase. The cycling
parameters were 94 °C for 10 min followed by 30 cycles of
94 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s. 2.5×104
AusDHBV genomes were amplified using DHBc-UCP and
DHBc-DCP to yield a PCR product of 818 bp that contained the
entire DHBc gene.
PCR mutagenesis of the pre-S/S gene prior to cloning into AF09
Analysis of the AusDHBV pre-S/S gene (Triyatni et al., 2001)
revealed two poxvirus transcription termination sequences, (T5)
NT, at nt 1344 and 1525 which were then mutated using PCR
(Higuchi et al., 1988) to prevent termination of transcription of
the cloned pre-S/S gene while maintaining the encoded amino
acid sequence. To enable directional cloning into the shuttle
vector pAF09, a BamHI restriction enzyme sequence was
included in the upstream cloning primer, pre-S/S-UCP, and a
HindIII restriction enzyme sequence was included in the down-
stream primer, pre-S/S-DCP (Table 1). The poxvirus transcrip-
tion terminator sequence, TTTTTAT, shown as its complimentary
sequence, (A5)TA, was also included in the downstream cloning
primer (Table 1). The final PCR product which was mutated and
cloned into pAF09 as described below included the entire DHBV
pre-S/S gene, nt 801–1793.
A series of stepwise PCR mutagenesis reactions were
performed to mutate the two (T5)NT terminators: (Reaction 1)
2.5×104 AusDHBV genomes were used as a template for PCR
amplification with the upstream mutating primer (pre-S/S-
UMP1) and the downstream cloning primer (pre-S/S-DCP)
(Table 1) to yield a product of 585 bp; (Reaction 2) 2.5×104
AusDHBV genomes were used as a template for PCR ampli-
fication with the upstream cloning primer (pre-S/S-UCP) and the
downstreammutating primer (pre-S/S-DMP1) (Table 1) with the
annealing temperature adjusted through optimization from 55 °C
to 53 °C to yield a PCR product of 96 bp; (Reaction 3) 50 ng
of each purified PCR product from Reactions 1 and 2 was used
as a template for PCR amplification with pre-S/S-UCP and pre-
S/S-DCP (Table 1) to yield a PCR product of 1026 bp, whichwas
purified and cloned into pBluescript (pBs-pre-S/S); (Reaction 4)
100 ng of pBs-pre-S/S was used as template for PCR
amplification with pre-S/S-UCP and the downstream mutating
primer (pre-S/S-DMP2) (Table 1) to yield a PCR product of
758 bp; (Reaction 5) 100 ng of pBs-pre-S/S was used as template
for PCR amplification with the upstream mutating primer (pre-
S/S-UMP2) and pre-S/S-DCP (Table 1) to yield a PCR product
of 302 bp; (Reaction 6) Finally, 50 ng of each of the two purified
PCR products from reactions 4 and 5 was used as a template
for PCR amplification with pre-S/S-UCP and pre-S/S-DCP
(Table 1) to yield a PCR product of 1026 bp.
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The vector pAF09 (Boyle et al., 2004) and the gel-purified
818 bp DHBc, or the 1026 bp pre-S/S PCR products described
above were digested with BamHI and HindIII, ligated and then
transformed into DH5-α to create plasmids pAF09-DHBc and
pAF09-pre-S/S (Fig. 1). Colonies were isolated and the plasmid
DNAwas sequenced using pAF09 forward primer (Seq. 1), and
reverse primer (Seq. 2) (Table 1) to confirm the correct identity
of the plasmids and the nucleotide changes introduced into the
pre-S/S gene by PCR mutagenesis (data not shown). Sequence
ladders were generated using 15 ng of template DNA and 8 μl of
Big Dye dideoxyterminator mix, with PCR cycling at 96 °C for
10 min, then 30 cycles of 96 °C for 10 min 50 °C for 10 min and
60 °C for 4 min. Sequences were determined using an ABI
Prism 377 DNA sequencer.
Preparation of primary chicken and duck embryo fibroblasts
Primary embryonic fibroblasts were isolated from 12-day-old
chicken (PCEF) and duck (PDEF) embryos as previously de-
scribed (Miller et al., 2006a,b; Vogt, 1969). Briefly, the embryos
were aseptically eviscerated; the remaining tissue was loosely
dissociated with a pipette then digested with 0.1% trypsin at
37 °C for 15 min and further dissociated to produce a cell
suspension. The primary fibroblasts were then plated in RPMI
1640 containing 12 μg/ml penicillin, and 16 μg/ml gentamycin,
plus 5% normal duck serum (PDEF) or 5% normal chicken
serum (PCEF) and grown overnight in a 5% CO2 incubator at
37 °C. The resulting monolayers were trypsinized, harvested and
stored in liquid nitrogen prior to use.
Derivation and confirmation of rFPV-M3 vaccine strains
expressing DHBc and pre-S/S antigens
The rFPV strains, rFPV-DHBc and rFPV-pre-S/S, were
created dominant selection protocols for the insertion of genetic
material into the FPV-M3 genome (Boyle et al., 2004): creation
of the strains involved homologous recombination between the
FPV thymidine kinase gene present within FPV-M3 strain and
pAF09-DHBc and pAF09-pre-S/S, followed by selection using
mycophenolic acid. Stocks of both rFPV-DHBc and rFPVpre-S/S
were grown in PCEF cell cultures and the titer of each virus stock
was determined as p.f.u. per ml. The expression of specific
DHBV proteins was confirmed byWestern blotting using PCEF
cell cultures (5×106 cells) infected with FPV-M3, rFPV-DHBc
or rFPV-pre-S/S at a multiplicity of infection (m.o.i.) of 5 p.f.u./
cell. At 96 h after infection the PCEF were harvested by
centrifugation at 2500×g for 10 min at 4 °C. The pellets were
taken up in 300 μl of PBS and samples were analyzed by
denaturing gel electrophoresis on NuPAGE Novex Bio-Tris 4–
12% gradient gels (Invitrogen). Proteins were transferred to
poly-vinylidene difluoride (PVDV)membranes and probed with
a 1/2000 dilution of polyclonal duck anti-DHBV antibodies
(Jilbert et al., 1992). Following a brief wash, rabbit anti-duck
IgY antibodies (Miller et al., 2004) were added at a dilution of
1/15000. Peroxidase-labeled goat anti-rabbit tertiary antibodiesat a dilution of 1/5000 were then added, followed by
chemilluminescent detection. Molecular weight markers,
MagicMark™ Western Standard and SeeBlue Plus2 Pre-
Standard (Invitrogen), were included on all gels. The expression
of specific DHBV proteins was also assessed by Western
blotting of PDEF infected with nil, FPV-M3, rFPV-DHBc or
rFPV-pre-S/S using a modified protocol. PDEF were grown in a
6well plates until they reached 85∼90% confluence. The culture
media were then replaced with 1 ml of fresh media (per well)
containing 2.5% fetal calf serum and∼4×107 p.f.u. of FPV-M3,
rFPV-DHBc or rFPV-pre-S/S, respectively. At 2 h after inoc-
ulation, the media were changed and the infected PDEF were
incubated for a further 48 h. The PDEF were then lysed with
50 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1%
NP40 and protease inhibitor cocktail (Roche, 1 tablet for 10 ml
lysis buffer). Cell lysates were separated by 12% SDS-PAGE
and subjected to Western blot analysis with either polyclonal
rabbit anti-DHBc antibodies (Jilbert et al., 1992) or monoclonal
anti-DHBV pre-S antibodies (Pugh et al., 1995). The protein
content of each lysate was compared by stripping of the
membranes followed by Western blotting with monoclonal anti-
human actin antibodies (CHEMICON #MAB1501R). The
secondary immunoreactions were performed with horseradish
peroxidise-conjugated goat anti-rabbit or goat anti-mouse
immunoglobulin G (Pierce) and detected using ECL™Western
blotting reagents (GE Healthcare).
Assessment of the FPV-M3, rFPV-DHBc and rFPV-pre-S/S
strains in cell culture
Monolayers of PCEF and PDEF were used to assess the
cytotoxicity, DHBV antigen production and FPV late gene
expression of the rFPV strains. 6×105 PCEF or PDEF were
plated into 48-well trays and allowed to attach overnight at
37 °C. The following day the media were removed and the
monolayers were infected with 5 p.f.u./cell of FPV-M3, rFPV-
DHBc or rFPV-pre-S/S. The virus was allowed to attach for 1 h
at 37 °C, the monolayers were then washed twice with PBS
before addition of the appropriate growth medium, and
incubated at 37 °C until assayed. Infected monolayers were
stained with 1% crystal violet after fixation in 100% methanol,
to assess cytopathicity. Separate cultures were stained for the
presence of B-galactosidase after fixation in 0.2% glutaralde-
hyde, by incubation in 1 mg/ml of X-gal in 5 mM potassium
ferricyanide and 2 mM magnesium chloride at 37 °C overnight.
For immunofluorescent detection of DHBc or pre-S/S expres-
sion, monolayers incubated for 24 h after infection were washed
with PBS, fixed with 95% methanol and blocked with 5% skim
milk/PBS for 1 h. The monolayers were then incubated with
primary antibodies, polyclonal rabbit anti-DHBc (Jilbert et al.,
1992) or monoclonal anti-DHBV pre-S antibodies (Pugh et al.,
1995), for 1 h at 37 °C. Following two PBS washes, the
monolayers were incubated with secondary antibodies, goat
anti-rabbit Alexa 488 (A-11008; Invitrogen) or goat anti-mouse
Alexa 488 (A-21121; Invitrogen), were washed with PBS and
were mounted in PBS containing 25% glycerol. Fluorescence
was detected with a UV microscope at 495 nm.
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The ability of the FPV-M3 strain to cause lesions in vivo was
assessed by inoculation of the wing web of ducks, the standard
industry practice for vaccine delivery in poultry. Inoculation of
the FPV-M3 vaccine strain into the wing web of chickens causes
local poxvirus lesions at the wing stab site over a 103–104 range
of vaccine dilutions (Boyle et al., 1997). Three, 7-day-old ducks
were inoculated via the wing web with a 22 G needle dipped
into a neat stock of FPV-M3 (5×108 p.f.u./ml). Three control
7-day-old ducks were housed in the same pen to assess the
possible transfer of FPV infection from duck-to-duck. All ducks
were monitored daily for 2 weeks following inoculation. No
signs of respiratory distress or lesions at the site of inoculation of
the wing web were observed in ducks. We concluded that
although the FPV-M3 strain replicates and causes clinical lesions
in chickens (Boyle et al., 1997), evidence of FPV lesions or
disease was not seen in the inoculated ducks or in their cage
controls.
DHBV challenge, antiviral drug administration and
vaccination regime
Four groups of 14-day-old ducks, Groups A to D, were
inoculated intravenously with 5×108 AusDHBV genomes as
previously described (Foster et al., 2003, 2005; Jilbert et al.,
1998, 1996, 1992; Meier et al., 2003; Miller et al., 2006a,b;
Triyatni et al., 1998). At the same time, oral treatment with ETV
(1.0mg/kg/day for 14 days) was commenced in Groups A and C.
Groups B and D were treated with water. A single “priming”
dose of DHBV DNA vaccine expressing DHBc, pre-S/S and
S antigens (500 μg of each construct) was administered intra-
muscularly (IM) to Group A and B at the time of infection,
followed at day 7 p.i. by a second IM “boost” dose of 5×107 p.f.u.
of both rFPV-DHBc and rFPV-pre-S/S. Groups C and D received
the control DNAvector (pcDNA1.1 Amp), followed on day 7 by
IM inoculation of 5×107 p.f.u. of rFPV-M3, the parent FPV
vaccine strain.
Analysis of serum and liver tissue
Serum samples were collected weekly and assayed for levels
of DHBsAg and anti-DHBs and anti-DHBc antibodies by
ELISA (Miller et al., 2004; Triyatni et al., 1998). To assess the
extent of DHBV infection in the liver, a wedge biopsy was
collected from each duck on day 4 and 14 p.i. Liver biopsy
samples were also taken from all ducks at autopsy at day 67 p.i.
Tissue fixation, embedding, sectioning and immunoperoxidase
staining of DHBsAg and staining with hematoxylin and eosin
were performed as previously described (Foster et al., 2003,
2005; Miller et al., 2004). Nuclei of hepatocytes staining pos-
itive for DHBsAg were counted and expressed as the percentage
of the average total hematoxylin stained hepatocyte nuclei in the
same fields using an eyepiece with a graticule. For each duck,
2000, 250×250 mm grid fields were counted resulting in min-
imum sensitivity of detection of 0.001% (Foster et al., 2005;
Meier et al., 2003). To assess the degree of liver inflammation,100, 250 mm×250 mm grid fields were counted using the 10X
objective lens. The percentage of each section that contained
infiltrating mononuclear cells was then calculated.
DNA extraction from liver tissue and quantitative PCR (qPCR)
for total DHBV DNA
Total cellular and viral DNA was extracted from 20 mg of
duck liver tissue using the DNeasy Tissue extraction kit (Qiagen)
as previously described (Foster et al., 2005; LeMire et al., 2005).
qPCR was performed on an ABI 7000 qPCR machine. The
reaction mix contained 10 μl of SYBR green PCR master mix
(Applied Biosystems), 5 μl of extracted DNA containing 150 ng
(equivalent of 52,000 cells), 10 μM of the forward primer,
qPCR-F, and reverse primer, qPCR-R (Table 1), and 3.8 μl of
DW. Standard curves were constructed using plasmid pBL4.8
containing the complete AusDHBV genome (Triyatni et al.,
2001) with 90 ng of plasmid DNA being equivalent to 1010
copies of DHBVDNA. Tenfold dilutions of the plasmid resulted
in a linear amplification curve between 108 and 101 copies (data
not shown). The PCR reaction included an initial 50 °C
denaturation step of 2 min and then 95 °C for 10 min. The
amplification program consisted of 40 cycles of 15 s at 95 °C and
1 min at 60 °C. Analysis of the data was performed using ABI
Prism 7000 SDS software. The minimum sensitivity of detection
was 10 copies of DHBV DNA in 52,000 cells or 0.0002 copies
of DHBV DNA/cell.
RNA extraction, quantitative reverse transcription
PCR (qRT-PCR) and primer design
Twenty-five milligram liver samples collected from ducks in
Groups A and B on days 4 and 14 p.i. were extracted using an
RNAqueous 4-PCR RNA extraction kit (Ambion). The
extracted RNA was collected into RNase-free centrifuge tubes
and treated with DNase I following the manufacturer's
instructions (RNAqueous 4-PCR RNA; Ambion). The reverse
transcription step from 1 μg of RNA into cDNAwas performed
using Reverse Transcription System (Promega). Primers were
designed for the detection of mRNA expression of the cytokines
duck IFN-α, IFN-γ and duck T-cell markers CD3, CD4 and
CD8, using duck GAPDH as an internal control (data not
shown, Reaiche et al., manuscript in preparation). qRT-PCR
was performed using a SYBR green PCR master mix (Applied
Biosystems) on an ABI prism 7000 real-time PCR machine.
The conditions for the qRT-PCR were 50 °C for 2 min followed
by 10 min at 95 °C with amplification of 40 cycles at 15 s at 95
°C and 1 min at 60 °C. The data were later analyzed using ABI
Prism 7000 SDS software.
Statistical analysis
The chi-square test was used to determine if there was a
statistically significant association between the percentages of
DHBV-infected hepatocytes in each treatment Group A-D. The
normally distributed outcome of the average number of DHBsAg-
positive hepatocytes in each Group was analyzed using a mixed
340 D.S. Miller et al. / Virology 373 (2008) 329–341model ANOVA to allow for repeatedmeasures over time. Post hoc
testing was used to look at pair-wise comparisons between the
treatments with no adjustment made for multiple comparisons.
Significance was assessed at the 5% level. All analyses were
performed using SAS version 9.1 (SAS Institute, Cary, NC,USA).
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